Supplier of high purity PEG derivatives and linkers, monodisperse PEG, ADC PEG linkers, PROTAC linkers, PEGylation services, etc.
Massachusetts, USA
Joined January 2017
- Tweets736
- Following403
- Followers165
- Likes303
🔬 Monodispersed PEG linkers for precise bioconjugation
✔ Defined MW & structure
✔ Strong solubility & low immunogenicity
✔ Flexible groups: Azide, Amine, NHS, Maleimide, BOC/FMOC, etc
g–kg scale | GMP available biochempeg.com/product/541/
#PEG #ADC #Bioconjugation
The ADC breakout was just the beginning. 🚀
With Enhertu nearing $5B in sales, the industry is officially pivoting to the XDC (Everything-Drug Conjugate) era.
From PDCs to RDCs and AOCs, the "modular" drug revolution is here. 🧬
biochempeg.com/article/1464.…
🌸 Multi-Arm PEG for PEGylation
Why Multi-arm PEG
✔ Larger hydrodynamic size
✔ Improved steric shielding
✔ Longer circulation time
Multiarm PEGs are explored in PEGylated therapeutics like IZERVAY, Skytrofa, YORVIPATH,etc
Explore our Multi-Arm PEG: biochempeg.com/product/546/
Happy New Year! Thank you to all our clients and partners for a great year. Wishing you success and growth in the year ahead.
#happynewyear #NewYear2026
🦃 This Thanksgiving, we just want to say thank you to everyone who’s been working with us this year.
To keep your projects moving:
• >95% purity, low impurities
• From gram to kg, at a fair price
🔗 biochempeg.com
📩 [email protected]
#Thanksgiving #PEG #ADC
📊 ADC Market Update H1 2025
Global sales hit ~$8B (FY 2025 est. >$16B)
Top sellers: Enhertu, Padcev, Kadcyla, Polivy, Adcetris, Trodelvy
41 ADCs in Phase III across 50+ targets 🚀
Rising stars: HER3, B7-H3, CLDN18.2, ROR1
👉 Full article: biochempeg.com/article/447.h…
#ADC #Oncology
Biopharma PEG Scientific Inc. retweeted
BETAMI–DANBLOCK trial: Beta-blockers are recommended for myocardial infarction and reduced left ventricular ejection fraction, but potential benefits for preserved or mildly reduced ejection fraction are unclear. Research findings are summarized in a new Quick Take video. nej.md/41DqahQ
ALT Visual representation of the BETAMI–DANBLOCK trial, which evaluated beta-blockers for preserved or mildly reduced ejection fraction.
3 of 19 approved ADCs use PEG linkers for stability & precision:
🔹 Trodelvy®
🔹 Zynlonta®
🔹 Jiataile® (China)
Biopharma PEG delivers >95% purity PEG linkers (impurities <0.5%) to power ADC innovation.
biochempeg.com/adc-conjugati…
Biopharma PEG Scientific Inc. retweeted
Breaking! The FDA has approved Wegovy #semaglutide to treat #MASH in adults with moderate-to-advanced fibrosis.
fda.gov/drugs/news-events-hu…
🚀 PROTACs are moving fast: 40+ candidates in trials, targeting AR, ER, BTK & more.
3 in Phase 3:
🔹 ARV-471 (FDA NDA, PDUFA June 2026)
🔹 BMS-986365
🔹 BGB-16673
biochempeg.com/article/434.h…
A new drug class may be just around the corner. 👀
#PROTAC #Oncology #DrugDiscovery
🔹 Y-shape-PEG-NHS (2-Arm PEG-NHS) enables efficient amine-reactive conjugation for proteins, peptides & hydrogels.
💡 Ideal for tissue engineering & controlled drug release.
👉 From lab to commercial scale: [email protected]
#PEGylation #Biotech #DrugDelivery #Hydrogels
Just revealed at #ACS2025: BMS-986238, a macrocyclic PD-L1 inhibitor with a PEG linker + C18 fatty acid for long half-life & oral potential.
Biopharma PEG supports such advances with custom PEGs for next-gen therapeutics.
🔗 biochempeg.com/article/441.h…
#PEGylation #BMS986238
Featured PEGs from Biopharma PEG!
✅ Monodispersed & Polydispersed
✅ GMP Grade
✅ From grams to 100 kg
🔗 biochempeg.com
📩 [email protected]
#PEGs #Biopharma #ADC #GMP
🚨 Big News!
Biopharma PEG’s HZ-PEG-HZ (1K) has received FDA Type II DMF approval (No. 041864) ✅
🔬 GMP-grade
📦 Supply: mg to 100 kg
💊 Ready to support global drug development!
biochempeg.com/article/438.h…
📩 [email protected]
#FDA #DMF #PEGylation #DrugDelivery #BiopharmaPEG
🚨 PROTAC 2025 Update!
Top degraders enter Phase 3:
🔹 ARV-471 (ER+)
🔹 BMS-986365 (AR)
🔹 BGB-16673 (BTK)
Targeting tough diseases with next-gen protein degradation tech.
Full story 👉 biochempeg.com/article/434.h…
#PROTAC #Oncology #Biotech #ARV471 #BMS986365 #BGB16673
🚀 Dual-payload ADCs = the next big leap in cancer therapy!
🎯 Two payloads, one antibody = more power, less resistance.
🔥 KH815 becomes the first to enter clinical trials.
biochempeg.com/article/432.h…
#ADC #CancerResearch #Oncology #Biotech #KH815 #DualPayloadADC #AACR2025
🚀 PEGylated lipids boost stability & circulation in mRNA vaccines, siRNA, & anti-cancer drugs! Their structure affects immune response & drug efficacy—a game-changer in #DrugDelivery.
💡 Discover Biopharma PEG’s high-quality PEG lipids today!
🔗 biochempeg.com/article/429.h…
#LNP
🚀 The #ADC market has surpassed $10B in sales! In 2024:
💥 Enhertu: $3.75B
💥 Kadcyla: $2.32B
💥 Padcev: $1.59B
💥 Adcetris: $1.91B
💥 Trodelvy: $1.31B (+24% from 2023)
17 ADC drugs are now approved worldwide! 🌍
🔗 Learn More: biochempeg.com/article/427.h…
#Biotech #CancerTherapy
🚨 FDA APPROVES Datroway (datopotamab deruxtecan) for HR-positive, HER2-negative breast cancer! 🎉 The 13th #ADC approval offering new hope for patients.
Thanks to AstraZeneca & Daiichi Sankyo for this major milestone!
biochempeg.com/article/424.h…
#FDAApproval #BreastCancer
